IL207127A0 - Aldh-2 inhibitors in the treatment of addiction - Google Patents
Aldh-2 inhibitors in the treatment of addictionInfo
- Publication number
- IL207127A0 IL207127A0 IL207127A IL20712710A IL207127A0 IL 207127 A0 IL207127 A0 IL 207127A0 IL 207127 A IL207127 A IL 207127A IL 20712710 A IL20712710 A IL 20712710A IL 207127 A0 IL207127 A0 IL 207127A0
- Authority
- IL
- Israel
- Prior art keywords
- aldh
- addiction
- inhibitors
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Addiction (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2008/051862 WO2009094028A1 (fr) | 2008-01-24 | 2008-01-24 | Inhibiteurs d'aldh-2 dans le traitement d'une accoutumance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL207127A0 true IL207127A0 (en) | 2010-12-30 |
Family
ID=39731733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL207127A IL207127A0 (en) | 2008-01-24 | 2010-07-21 | Aldh-2 inhibitors in the treatment of addiction |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2254878A1 (fr) |
| JP (1) | JP2011510072A (fr) |
| KR (1) | KR20100130589A (fr) |
| CN (1) | CN101925590A (fr) |
| AU (1) | AU2008348372A1 (fr) |
| BR (1) | BRPI0822129A2 (fr) |
| CA (1) | CA2712750A1 (fr) |
| EC (1) | ECSP10010417A (fr) |
| IL (1) | IL207127A0 (fr) |
| MA (1) | MA32095B1 (fr) |
| MX (1) | MX2010008111A (fr) |
| WO (1) | WO2009094028A1 (fr) |
| ZA (1) | ZA201004671B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102161648A (zh) * | 2011-02-18 | 2011-08-24 | 中国药科大学 | 具有选择性雌激素受体调节活性的异黄酮类化合物的制备方法及其用途 |
| TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
| AR087700A1 (es) * | 2011-08-30 | 2014-04-09 | Gilead Sciences Inc | Inhibidores de aldh-2 en el tratamiento de adicciones |
| KR20200070273A (ko) * | 2017-10-16 | 2020-06-17 | 아미그달라 뉴로사이언시즈, 인크. | 중독을 예방하기 위한 병용 요법 |
| CN108276374B (zh) * | 2018-03-29 | 2020-01-31 | 天津科技大学 | 黄酮类芳香化酶抑制剂及其制备方法与应用 |
| CN110922394B (zh) * | 2019-11-21 | 2021-04-06 | 中国科学院宁波材料技术与工程研究所 | 一种基于天然黄酮类化合物的生物基本征阻燃环氧树脂前驱体及其制备方法和应用 |
| WO2023235753A2 (fr) * | 2022-05-31 | 2023-12-07 | University Of Maryland, Baltimore | Inhibiteurs d'aldh2 et leurs procédés d'utilisation |
| WO2023244574A1 (fr) | 2022-06-14 | 2023-12-21 | Amygdala Neurosciences, Inc. | Composés inhibiteurs d'aldh-2 et procédés d'utilisation |
| WO2023244563A1 (fr) | 2022-06-14 | 2023-12-21 | Amygdala Neurosciences, Inc. | Composés inhibiteurs d'aldh-2 et procédés d'utilisation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU162377B (fr) * | 1970-05-27 | 1973-02-28 | ||
| US4166862A (en) * | 1971-05-25 | 1979-09-04 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Animal feed containing anabolic isoflavones |
| GB8626344D0 (en) * | 1986-11-04 | 1986-12-03 | Zyma Sa | Bicyclic compounds |
| US5204369A (en) * | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
| DE69932427T2 (de) * | 1998-05-12 | 2007-02-22 | The Endowment for Research in Human Biology, Inc., Boston | Verfahren und testen verwendbar bei der behandlung von alkoholabhängigkeit oder -missbrauch |
| WO2004001058A2 (fr) * | 2001-05-04 | 2003-12-31 | Paratek Pharmaceuticals, Inc. | Composes modulateurs de facteurs de transcription et procedes d'utilisation |
| AUPR957001A0 (en) * | 2001-12-19 | 2002-01-24 | Novogen Research Pty Ltd | Isoflavone conjugates, derivatives thereof and therapeutic methods involving same |
| CN1671373A (zh) * | 2002-06-27 | 2005-09-21 | 人类生物研究基金公司 | 用于抑制aldh的化合物 |
| EP2277595A3 (fr) * | 2004-06-24 | 2011-09-28 | Novartis Vaccines and Diagnostics, Inc. | Composés pour potentialiser l'immunité |
| PL377180A1 (pl) * | 2005-09-21 | 2007-04-02 | Instytut Farmaceutyczny | Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz |
| KR20090033417A (ko) * | 2006-07-27 | 2009-04-03 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 중독의 치료에서의 ａｌｄｈ-2 저해제 |
| BRPI0820440A2 (pt) * | 2007-11-06 | 2015-05-26 | Cv Therapeutics Inc | Inibidores aldh-2 no tratamento de desordens psiquiátricas |
-
2008
- 2008-01-24 KR KR1020107016579A patent/KR20100130589A/ko not_active Application Discontinuation
- 2008-01-24 AU AU2008348372A patent/AU2008348372A1/en not_active Abandoned
- 2008-01-24 BR BRPI0822129-4A patent/BRPI0822129A2/pt not_active IP Right Cessation
- 2008-01-24 JP JP2010544284A patent/JP2011510072A/ja active Pending
- 2008-01-24 CN CN200880125439XA patent/CN101925590A/zh active Pending
- 2008-01-24 WO PCT/US2008/051862 patent/WO2009094028A1/fr active Application Filing
- 2008-01-24 MX MX2010008111A patent/MX2010008111A/es not_active Application Discontinuation
- 2008-01-24 CA CA2712750A patent/CA2712750A1/fr not_active Abandoned
- 2008-01-24 EP EP08713963A patent/EP2254878A1/fr not_active Withdrawn
-
2010
- 2010-07-02 ZA ZA2010/04671A patent/ZA201004671B/en unknown
- 2010-07-21 IL IL207127A patent/IL207127A0/en unknown
- 2010-08-23 EC EC2010010417A patent/ECSP10010417A/es unknown
- 2010-08-23 MA MA33106A patent/MA32095B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA32095B1 (fr) | 2011-02-01 |
| WO2009094028A1 (fr) | 2009-07-30 |
| MX2010008111A (es) | 2010-11-30 |
| ECSP10010417A (es) | 2010-11-30 |
| CN101925590A (zh) | 2010-12-22 |
| BRPI0822129A2 (pt) | 2015-06-23 |
| ZA201004671B (en) | 2011-03-30 |
| KR20100130589A (ko) | 2010-12-13 |
| JP2011510072A (ja) | 2011-03-31 |
| EP2254878A1 (fr) | 2010-12-01 |
| CA2712750A1 (fr) | 2009-07-30 |
| AU2008348372A1 (en) | 2009-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL195400A0 (en) | Aldh-2 inhibitors in the treatment of addiction | |
| IL230683A0 (en) | dpp-iv inhibitors for use in the treatment of nafld | |
| IL208354A0 (en) | Methods of treatment | |
| EP2361089A4 (fr) | Compositions et procédés pour le traitement d une fonction altérée de l' -synucléine | |
| IL212348A0 (en) | Treatment method | |
| EP2200977A4 (fr) | Inhibiteur de f1f0-atpase et procédés associés | |
| GB0802116D0 (en) | Treatment | |
| EP2308884A4 (fr) | Procédé de production d'un alkylhalogénohydrosilane substitué par un groupement hétéro en et son utilisation | |
| IL213619A0 (en) | Treatment | |
| EP2300011A4 (fr) | Procédés et composés thérapeutiques | |
| HK1149933A1 (en) | Diazacarbazoles and methods of use | |
| IL207127A0 (en) | Aldh-2 inhibitors in the treatment of addiction | |
| GB0822011D0 (en) | Treatment | |
| GB0819280D0 (en) | Imgaing and radiotherapy methods | |
| IL209548A0 (en) | Diazacarbazoles and methods of use | |
| GB0807018D0 (en) | Antibodies and treatment | |
| GB0811992D0 (en) | Treatment | |
| GB0918601D0 (en) | Decahydro-1H-Indenoquinolinone and decahydro-3H-cyclopenaphenanthridinone CYP17 inhibitors | |
| IL208611A0 (en) | Device and process for the formation of microdepositions | |
| EP2512504A4 (fr) | Composition et méthode thérapeutique | |
| HK1199729A1 (en) | Aldh-2 inhibitors in the treatment of addiction aldh-2 | |
| EP2164494A4 (fr) | Procédés de traitement | |
| HK1167406A1 (en) | Pyrazolone-derivatives and their use as pd4 inhibitors pd4 | |
| GB0820972D0 (en) | Treatment | |
| GB0805912D0 (en) | Treatment |